pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

IPSEN

USupdated 3mo ago
Website ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranornot yet recruitingn=50
  • —Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancyrecruitingn=3
  • —A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatmentrecruitingn=30
  • —A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatmentrecruitingn=30
  • —A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatmentactive not recruitingn=424
  • phase3A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitisrecruitingn=350
  • phase3Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)active not recruitingn=161
  • phase2Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitorscompletedn=127
🐶 Hiring Signal
No open roles indexed yet — view IPSEN jobs →

News

  • Charles River teams up with Ipsen to use virtual control groups in toxicology studies
    Charles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma company Ipsen.
    fiercebiotech · 12d ago
  • Looking Beyond the First Answer Towards Delivering Impact
    Science rarely moves in a straight line. Philippe Lopes-Fernandes explores how an unexpected turn can reveal a credible path to progress.
    fiercebiotech · 25d ago
  • PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
    A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
    biopharma_dive · 1mo ago
  • FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
    The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…
    biospace · 1mo ago
  • 9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
    Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”
    biopharma_dive · 1mo ago
  • STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
    Novo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines
    stat · 1mo ago
  • Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
    Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.
    fiercebiotech · 2mo ago
  • Regeneron to challenge Ipsen as FDA clears bone disease drug
    Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
    biopharma_dive · 2mo ago
  • Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
    Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
    biospace · 2mo ago
  • Slate, Fulcrum to combine in reverse merger
    Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.
    biopharma_dive · 3mo ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?